Poster Schedule

9:45 AM - 1:30 PM PT

(1) Successful Implementation of HCV Point-of-Care Testing in a Syringe Services Program

9:45 AM - 1:30 PM PT

(2) PrEP Eligibility Among People Who Use Drugs Accessing Opioid Treatment Programs

9:45 AM - 1:30 PM PT

(3) HIV/PrEP Knowledge, Perceived Risk, and Attitudes Among PWID After a Hospital Intervention

9:45 AM - 1:30 PM PT

(4) Optimizing Geographic Naloxone Distribution to Reduce Opioid Overdose Deaths

9:45 AM - 1:30 PM PT

(5) EMS-Attended Overdoses Before and After the COVID-19 Pandemic in Camden, New Jersey

9:45 AM - 1:30 PM PT

(6) Perceptions of Harm Reduction Integration in Treatment: A Qualitative Study

9:45 AM - 1:30 PM PT

(7) Stigma and Treatment Engagement in Addiction Medicine: Pilot Findings Across Stigma Domains

9:45 AM - 1:30 PM PT

(8) Naloxone Vending at Jail Release Works Without Mandatory Overdose Education

9:45 AM - 1:30 PM PT

(9) Determinants of Naloxone Favorability and Carrying in the General Public

9:45 AM - 1:30 PM PT

(10) Patient-Centered Design: Improving Naloxone Access Through Patient Insights

9:45 AM - 1:30 PM PT

(11) Pre-EMS Naloxone Administrator Role and Predictors of Receiving Subsequent Naloxone by EMS

9:45 AM - 1:30 PM PT

(12) Real-World Analysis of Buprenorphine-Precipitated Opioid Withdrawal: A Multicenter Study

9:45 AM - 1:30 PM PT

(13) Addiction-Informed Opioid-Sparing Pain Care in the ED: ED-ALT Outcomes

9:45 AM - 1:30 PM PT

(14) OPRD1 rs678849 Predicts Buprenorphine Outcomes in an ED-Initiated MOUD Program

9:45 AM - 1:30 PM PT

(15) Extracting Post-Opioid Overdose Care from ED Encounters Using Large Language Models

9:45 AM - 1:30 PM PT

(16) Self-Reported Effects Associated With Xylazine/Medetomidine in Drug Checking Samples

9:45 AM - 1:30 PM PT

(17) Xylazine-Adulterated Fentanyl in Pregnancy: Postpartum Withdrawal With GI Hemorrhage

9:45 AM - 1:30 PM PT

(18) Xylazine in the Fentanyl Era: Patient Perspectives on Methadone and Emergency Care

9:45 AM - 1:30 PM PT

(19) Maternal and Fetal Effects Associated With Perinatal Xylazine Exposure: A Systematic Review

9:45 AM - 1:30 PM PT

(20) Methadone as Treatment for Tianeptine Withdrawal

9:45 AM - 1:30 PM PT

(21) Tianeptine Misuse: Systematic Review of Clinical Features, Withdrawal, and Management

9:45 AM - 1:30 PM PT

(22) Recovery is WORTH IT: Data from a Statewide Low-Threshold Buprenorphine Telehealth Program

9:45 AM - 1:30 PM PT

(23) Impact of Implementation Strategies on Collaboration Between Drug Courts and MOUD Providers

9:45 AM - 1:30 PM PT

(24) Impact of MOUD on Mental Health and Counseling Services in Jails

9:45 AM - 1:30 PM PT

(25) Buh-Bylazine! Xylazine Positivity Rate Change Among Patients in a Low-Barrier Access Clinic

9:45 AM - 1:30 PM PT

(26) Overcoming Barriers to Outpatient Buprenorphine Treatment for Opioid Use Disorder

9:45 AM - 1:30 PM PT

(27) Perceptions of Psilocybin Assisted Therapy (PAT) for Substance Use Disorder

9:45 AM - 1:30 PM PT

(28) Inpatient Discharge Prescribing and Early Engagement Predict Buprenorphine Continuation

9:45 AM - 1:30 PM PT

(29) Buprenorphine Dose and Pain Outcomes in Opioid Use Disorder and Chronic Pain

9:45 AM - 1:30 PM PT

(30) Barriers Persist: MOUD Knowledge, Attitudes, & Prescribing in North Carolina Family Medicine

9:45 AM - 1:30 PM PT

(31) An Open Label Pilot RCT of Low- vs High-Dose Telemedicine Buprenorphine Initiation

9:45 AM - 1:30 PM PT

(32) AI-Standardized Patient Reveals Practice Gaps After REMS-Aligned OUD Training

9:45 AM - 1:30 PM PT

(33) Characteristics of Pregnant Individuals Receiving Long-Acting Injectable Buprenorphine

9:45 AM - 1:30 PM PT

(34) Opioid Use Disorder Treatment Model: Access to Healthcare Barrier Survey

9:45 AM - 1:30 PM PT

(35) Assessing the Effects of Sublingual Buprenorphine on Dental Caries

9:45 AM - 1:30 PM PT

(36) Human Laboratory Evaluation of Direct-to-Inject XR-Buprenorphine: Preliminary Results

9:45 AM - 1:30 PM PT

(37) Advancing Access to Long-Acting Injectable Buprenorphine Through Community Pharmacies

9:45 AM - 1:30 PM PT

(38) Co-Located Bridge Clinic/Withdrawal Management Unit Reduces 30-Day Readmits Using LA-Bup Injections

9:45 AM - 1:30 PM PT

(39) High Retention Over 24 Months in Telehealth-Only Buprenorphine Program

9:45 AM - 1:30 PM PT

(40) Successful Buprenorphine Microinduction in Patient With Severe Kratom (7-OH) Use Disorder

9:45 AM - 1:30 PM PT

(41) Kratom Use in ADHD: A Case Highlighting Stimulant and Injectable-Buprenorphine Initiation

9:45 AM - 1:30 PM PT

(42) A Case of Baclofen-Managed Phenibut Dependence With Concurrent Opioid Use Disorder

9:45 AM - 1:30 PM PT

(43) Stigma as a Barrier to Early Retention in MOUD Treatment

9:45 AM - 1:30 PM PT

(44) Initiating Methadone for the Incarcerated: Implementation at Allegheny County Jail

9:45 AM - 1:30 PM PT

(45) Rapid Methadone Titration Protocols in Opioid Use Disorder: A Systematic Review

9:45 AM - 1:30 PM PT

(46) QTc Prolongation of Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder

9:45 AM - 1:30 PM PT

(47) Risk Reduction in Methadone Clinics: Addressing the Complexities of Opioid Use Disorder

9:45 AM - 1:30 PM PT

(48) Accelerating Access: A Rapid Methadone Protocol for Outpatient Care

9:45 AM - 1:30 PM PT

(49) Patient Experiences With a Low-Threshold Mobile Medical Unit for Opioid Use Disorder

9:45 AM - 1:30 PM PT

(50) Real-World Healthcare Utilization With SROM Versus Methadone: A Target Trial Emulation

9:45 AM - 1:30 PM PT

(51) Effectiveness and Key Components of Recovery Communities: A Rapid Review

9:45 AM - 1:30 PM PT

(52) Addiction Treatment Program Quality Measures: Results of a NIDA-Funded Study

9:45 AM - 1:30 PM PT

(53) Impact of OAT in Individuals With OUD Who Experienced Overdose in Ontario

9:45 AM - 1:30 PM PT

(54) Current Practice Patterns for Treating Alcohol Use Disorder in US Emergency Departments

9:45 AM - 1:30 PM PT

(55) Increased Naltrexone Prescribed for Alcohol Use After Changes to Obesity Treatment Protocol

9:45 AM - 1:30 PM PT

(56) Expanding Screening and Treatment for Alcohol Use Disorder for Undocumented Latinx Patients

9:45 AM - 1:30 PM PT

(57) Confluence of Discrimination and Belongingness in LGBTQ+ Substance Use

9:45 AM - 1:30 PM PT

(58) Denied at the Door: Accessibility of Substance Use Treatment Facilities

9:45 AM - 1:30 PM PT

(59) Disability Rights Training for Peer Support Specialists: A Prospective Survey Study

9:45 AM - 1:30 PM PT

(60) Substance Use Among Adolescents in Pediatric Primary Care

9:45 AM - 1:30 PM PT

(61) New Extremely High Urine Cotinine Levels in Adolescents Who Vape Nicotine

9:45 AM - 1:30 PM PT

(62) Comorbidities and Mortality in Substance Use Disorder Patients With Nicotine Dependence

9:45 AM - 1:30 PM PT

(63) No Better Time Than the Present: Helping Hospitalized Veterans Quit Smoking

9:45 AM - 1:30 PM PT

(64) Local Policy Matters: Structural Violence, Vaping, and Immigrant-Inclusive Protections

9:45 AM - 1:30 PM PT

(65) Tobacco-Stimulant Co-Use Among US Adults: National Trends and Persistent Role of Tobacco

9:45 AM - 1:30 PM PT

(66) Mixed-Methods Contingency Management for Smoking in Perinatal Opioid Use Disorder

9:45 AM - 1:30 PM PT

(67) Impact of Contingency Management on Retention in Outpatient SUD Programs

9:45 AM - 1:30 PM PT

(68) Mobilizing Contingency Management for Stimulant Use Disorder in the Street Medicine Setting

9:45 AM - 1:30 PM PT

(69) Contingency Management in Community Primary Care: An Essential and Successful Integration

9:45 AM - 1:30 PM PT

(70) Ketamine for Co-Cccurring Major Depressive and Alcohol Use Disorders: A Systematic Review

9:45 AM - 1:30 PM PT

(71) High Completion and Patient Satisfaction in a Virtual Ambulatory Alcohol Detox Program

9:45 AM - 1:30 PM PT

(72) Ketamine Effects on Anxiety and Drug Seeking Behaviors in Methamphetamine-Withdrawn Rats

9:45 AM - 1:30 PM PT

(73) Prenatal Methamphetamine Exposure and Intracranial Hemorrhage in Infants

9:45 AM - 1:30 PM PT

(74) Sensory Processing Sensitivity and Substance Use Disorder: A Multidimensional Exploration

9:45 AM - 1:30 PM PT

(75) Advancing Clinician-Informed, Symptom-Specific Approaches to Opioid Withdrawal Care

9:45 AM - 1:30 PM PT

(76) Bridging the Divide: A Telemedicine Bridge Clinic Improves Access to OUD Care

9:45 AM - 1:30 PM PT

(77) Increased Healthcare Utilization and Acuity Associated With Medetomidine

9:45 AM - 1:30 PM PT

(78) Relations Between Cannabis Craving, Distress Intolerance, And Coping Motives: A Pilot Study

9:45 AM - 1:30 PM PT

(79) Disparities in Adolescent Cannabis Treatment Admissions by the Criminal Justice System

9:45 AM - 1:30 PM PT

(80) SBIRT Model to Combine Direct Early Intervention and mHealth for Substance-Involved Youth

9:45 AM - 1:30 PM PT

(81) Screening, Brief Intervention, and Referral to Treatment Dose Effects in Foster Youth

9:45 AM - 1:30 PM PT

(82) The Relationship Between Problematic Internet Use and Substance Use in Adolescents

9:45 AM - 1:30 PM PT

(83) Polysubstance Use Among New York Transition-Age Adults Who Use Opioids, 2018–2024

9:45 AM - 1:30 PM PT

(84) An Educational Intervention to Improve Trainee Confidence in Managing Opioid Withdrawal

9:45 AM - 1:30 PM PT

(85) Treatment First: Early Trends in Use of Opioid Settlement Funds Across USA

9:45 AM - 1:30 PM PT

(86) Health Claims and Marketing Practices in the Online Kratom Marketplace

9:45 AM - 1:30 PM PT

(87) Relationship Conflict Reduces Recovery Capital: Oregon 2SLGBTQIA+ Community Findings

9:45 AM - 1:30 PM PT

(88) Access to Urban Setting AA Meetings Reflects Income, Race, and Educational Disparities

9:45 AM - 1:30 PM PT

(89) Participant Perspectives of a Peer Recovery-Enhanced Jail MAT Program

9:45 AM - 1:30 PM PT

(90) Opioid Management Review Committee Enhances Addiction Competencies in Palliative Care

9:45 AM - 1:30 PM PT

(91) Written Exposure Therapy for PTSD Increases Recovery Capital for Adults With SUD

9:45 AM - 1:30 PM PT

(92) Reducing Hospital Costs and Improving Access to Care With Hotel Vouchers

9:45 AM - 1:30 PM PT

(93) Words Matter: Results of a Stigma Reduction Initiative in a Safety-Net System

9:45 AM - 1:30 PM PT

(94) When Hot Flashes Are Not Withdrawal: Perimenopause in Opioid Use Disorder